What are Liquid Yield Option™ Notes (LYONs)?

Liquid Yield Option™ Notes (LYONs) are a type of zero-coupon, senior, convertible bond. They are issued at a deep discount to their face value and do not pay periodic interest. Instead, their value accretes over time, and they offer holders the option to convert them into a fixed number of common shares of the issuing company's stock. In this case, Amgen is offering to repurchase them directly rather than waiting for maturity or conversion.

Why is Amgen offering to repurchase these LYONs?

While the filing doesn't state the specific reasons, companies typically conduct tender offers to repurchase debt for several strategic reasons. These can include managing their debt maturity profile, reducing interest expense (especially for zero-coupon bonds where the discount represents interest), optimizing their capital structure, or believing the debt is undervalued in the market and repurchasing it is financially advantageous.

What is the specific price Amgen is offering for the LYONs?

Amgen is offering to purchase the LYONs at a price of $738.68 per $1,000 principal amount at maturity outstanding. This price is fixed for all holders who choose to tender their notes before the deadline.

What action do investors holding these LYONs need to take if they wish to sell?

Investors holding Amgen's Liquid Yield Option™ Notes due 2032 who wish to sell them must tender their notes to Amgen as part of the tender offer. They should refer to the details provided in Amgen's Schedule TO-I filing and the accompanying materials for the exact procedure and deadline, which is March 1, 2005, at 5:00 p.m. New York City time.

AMGN 8-K SEC Disclosure

Summary

Amgen Inc. has filed a Current Report on Form 8-K to announce a tender offer for its Liquid Yield Option™ Notes due 2032 (LYONs). The company is offering to purchase these notes at a price of $738.68 per $1,000 principal amount at maturity, at the option of the holders. This tender offer provides an opportunity for holders of these specific notes to sell them back to Amgen within a defined period. The offer commences on January 31, 2005, and will terminate on March 1, 2005, at 5:00 p.m. New York City time. This action suggests Amgen is managing its debt obligations and potentially seeking to reduce its outstanding long-term liabilities related to these convertible notes. Investors holding these LYONs should carefully review the terms and conditions of the tender offer detailed in Amgen's Schedule TO-I filing to determine if tendering their notes aligns with their investment strategy. The offer is a voluntary option for noteholders, and the repurchase price is fixed, providing certainty for those who choose to participate.

Key Highlights

1Amgen announced a tender offer for its Liquid Yield Option™ Notes due 2032 (LYONs).
2The offer allows holders to sell LYONs back to Amgen at $738.68 per $1,000 principal amount at maturity.
3The tender offer period begins on January 31, 2005.
4The offer will expire on March 1, 2005, at 5:00 p.m. New York City time.
5Amgen filed a Tender Offer Statement on Schedule TO-I with the SEC regarding this repurchase.
6This action indicates Amgen is proactively managing its debt structure.

AMGEN INC 8-K Report, Corporate Update (Jan 31, 2005)

Summary

Key Highlights

Frequently Asked Questions